CARLSBAD, Calif.--(BUSINESS WIRE)--Advanced Brain Monitoring, Inc. announces its recognition as the “Most Innovative Medical Device Company” by Global Health and Pharma for its 2016 Healthcare and Pharmaceutical awards. “This award recognizes our Company’s successes in developing technologies which enable clinicians and clinical trial sponsors to profile brain health through the analysis of the brain’s electrical activity (EEG) during sleep and wake,” stated Chris Berka, Chief Executive Officer.
The company’s platform includes streamlined EEG acquisition, secure transmission over a cloud portal and rapid analyses and reporting. The functional Neuro-Electrophysiological ImagingTM (fNEI) simultaneously measures EEG during resting state or with concurrent neurocognitive tests to activate the neural circuits involved in attention, memory and emotion. Quantified data can be compared to a database of more than 10,000 sessions from healthy and impaired populations. “Preliminary results reveal potential for estimating the severity of brain impairment for Alzheimer’s and Parkinson’s disease, mild cognitive impairment, and Frontotemporal dementia,” reported Philip Westbrook, Chief Medical Officer.
Sleep ProfilerTM explores the functioning of the brain during sleep and detects biomarkers associated with neurodegeneration and chronic diseases. Clinical applications include objectively assessing efficacy of prescription sleeping aids for patients with insomnia or the impact of anti-depressants and antihypertensive medications on sleep quality. “Sleep Profiler biomarkers have also been associated with the brain patterns of intensive care unit (ICU) patients who had sepsis or died,” commented Daniel J. Levendowski, President. “Sleep Profiler will soon enable the real-time monitoring of abnormal sleep patterns in ICU patients.”
The Company was recently awarded a $1.5 mm grant from National Institute of Health (NIH) to expand its database of awake and sleep EEG in patients with neurodegenerative diseases. “The envisioned future is for routine brain health assessments during sleep and waking to be conducted in a manner similar to a mammogram or colonoscopy,” stated Ms. Berka. “Ultimately, early detection will increase the likelihood that an intervention can be matched to the patient based on the presence of brain biomarkers and administered prior to the onset of cognitive decline.”
For over 15 years, Advanced Brain Monitoring has led the discovery of neuroscience applications to measure and interpret brain function, detect abnormal neuro-cardio respiratory response during sleep, and devices that improve sleep quality and enhance performance. With funding provided by the NIH, Department of Defense Advanced Research Projects Agency (DARPA), and other government agencies, the Company’s research has been reported in over 100 scientific publications and its discoveries resulting in 27 patents. The Company products include six FDA-cleared, CE-marked medical systems distributed throughout North America, Europe, Asia and Australia. Medical devices designed by the Company have now been used to assess and treat over 1.5 mm patients world-wide.
About the Global Brain Monitoring Market
According to MarketsandMarkets, the global brain monitoring market is projected to grow at a compounded 7% per year, from $7.5 billion in 2015 to $11.5 Billion by 2020. Key market players include Natus Medical, Nihon Kohden Corporation, Philips Healthcare, GE Healthcare, Siemens Healthcare, Medtronic, and Advanced Brain Monitoring.